Business Opportunities and Investment Strategies for Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ 2023-2033

Publication ID:

GRM0324009

Publication Date:

April 30, 2024

Pages:

187

Publisher:

Grace ﾂ鮓ｹﾔｭｴｴ Data

Countries:

Global [1]

USD 3,800.00

Healthcare [2]

Medical Devices [3]

Pharma & Healthcare [4]

Description:

Opportunity and Strategy Analysis
This report focuses on identifying opportunities and strategies for investing in the global pain management drugs market within the forecast period. It provides a complete analysis of the global market both quantitatively and qualitatively. The quantitative analysis includes market size and revenue data of the total demand, sub-markets, and regional/national levels throughout 2023-2033. Qualitative analysis depicts a full picture of market dynamics and trends including drivers, restraints and challenges, emerging products/market trends, and Porter窶冱 Fiver Forces analysis.

Based on the market data and analysis, the report highlights Increasingly Attractive Segments (IAS) and business opportunities in each segmentation. Moreover, a systematic evaluation of Internal Risks (factors arising within the industry development) and External Risks (factors arising from the surrounding environments) is provided for the pain management drugs industry and market. All the identified risk factors are measured quantitatively according to GMD窶冱 novel numeric system, i.e. each risk is evaluated with GMD Risk Index Number (GMD RIN) and GMD Risk Intensity Level (GMD RIL). This in-depth risk assessment offers a comprehensive understanding of the current risk factors and their developing trends. Furthermore, this report concludes risk management strategies and Critical Success Factors (CSFs) to help companies make intelligence-based business decisions in the global pain management drugs industry.

ﾂ鮓ｹﾔｭｴｴ Coverage & Overview
The report is based on studies for 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. Considering impact of COVID-19 and regional conflicts such as Russia-Ukraine war, the trend and outlook of global market is forecast in optimistic, balanced, and conservative scenarios. In the balanced view, the global pain management drugs market is expected to reach $121 billion by 2033, growing by 4.3% annually over the coming years.

Segmentation Analysis
Highlighted with 89 tables and 103 figures, this 187-page report represents a 360-degree view on the global market with extensively detailed segmentations by Product, Pain Type, Drug Type, Route of Administration, Application, Distribution Channel, and Region/Country as shown below. Annual revenue 2023-2033 for each segment is included in the report.

By Product
窶｢ Opioids
窶｢ NSAIDS
窶｢ Anesthetics
窶｢ Anticonvulsants
窶｢ Anti-depressants
窶｢ Non-narcotic Analgesics

By Pain Type
窶｢ Chronic Pain
窶｢ Acute Pain

By Drug Type
窶｢ Generic Drugs
窶｢ Branded Drugs

By Route of Administration
窶｢ Oral
窶｢ Parental

By Application
窶｢ Neuropathic Pain
窶｢ Cancer Pain
窶｢ Facial Pain and Migraine
窶｢ Musculoskeletal Pain
窶｢ Post-operative Pain
窶｢ Chronic Back Pain
窶｢ Arthritic Pain
窶｢ Other Applications

By Distribution Channel
窶｢ Hospitals Pharmacy
窶｢ Online Pharmacy
窶｢ Retail Pharmacy

By Region
窶｢ North America (U.S., Canada, and Mexico)
窶｢ Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
窶｢ APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
窶｢ South America (Brazil, Chile, Argentina, Rest of South America)
窶｢ MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
The breakdown of all regional markets by country and the breakdown of each national market by Product, Drug Type, and Application over the forecast years are also included.

Key Companies
The report also covers the current competitive scenario and profiles key vendors including market leaders and important emerging players. A selection of companies profiled in this report includes:
窶｢ Abbott Laboratories Inc.
窶｢ Baxter International Inc.
窶｢ Boehringer Ingelheim International GmbH
窶｢ Eli Lilly & Company
窶｢ GlaxoSmithKline PLC
窶｢ Johnson & Johnson
窶｢ Merck & Co. Inc.
窶｢ Novartis AG
窶｢ Pfizer Inc.
窶｢ Purdue Pharma L.P
窶｢ Teva Pharmaceutical Industries Ltd.

Table Of Contents:

1 Introduction 10
1.1 Industry Definition and Research Scope 10
1.1.1 Industry Definition 10
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of ﾂ鮓ｹﾔｭｴｴ Research Methodology 14
1.2.2 ﾂ鮓ｹﾔｭｴｴ Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 16
1.2.6 ﾂ鮓ｹﾔｭｴｴ Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 ﾂ鮓ｹﾔｭｴｴ Overview and Dynamics 22
2.1 ﾂ鮓ｹﾔｭｴｴ Size and Forecast 22
2.1.1 Impact of COVID-19 on World Economy 23
2.1.2 Impact of COVID-19 on the ﾂ鮓ｹﾔｭｴｴ 27
2.1.3 Impact of Russia-Ukraine Conflict 29
2.1.4 Impact of Israel-Palestine War 31
2.2 Major Growth Drivers 32
2.3 ﾂ鮓ｹﾔｭｴｴ Restraints and Challenges 37
2.4 Emerging Opportunities and ﾂ鮓ｹﾔｭｴｴ Trends 40
2.5 Porter窶冱 Fiver Forces Analysis 43
3 Segmentation of Global ﾂ鮓ｹﾔｭｴｴ by Product 47
3.1 ﾂ鮓ｹﾔｭｴｴ Overview by Product 47
3.2 Opioids 50
3.3 NSAIDS 51
3.4 Anesthetics 52
3.5 Anticonvulsants 53
3.6 Anti-depressants 54
3.7 Non-narcotic Analgesics 55
4 Segmentation of Global ﾂ鮓ｹﾔｭｴｴ by Pain Type 56
4.1 ﾂ鮓ｹﾔｭｴｴ Overview by Pain Type 56
4.2 Chronic Pain 59
4.3 Acute Pain 60
5 Segmentation of Global ﾂ鮓ｹﾔｭｴｴ by Drug Type 61
5.1 ﾂ鮓ｹﾔｭｴｴ Overview by Drug Type 61
5.2 Generic Drugs 64
5.3 Branded Drugs 65
6 Segmentation of Global ﾂ鮓ｹﾔｭｴｴ by Route of Administration 66
6.1 ﾂ鮓ｹﾔｭｴｴ Overview by Route of Administration 66
6.2 Oral 69
6.3 Parental 70
7 Segmentation of Global ﾂ鮓ｹﾔｭｴｴ by Application 71
7.1 ﾂ鮓ｹﾔｭｴｴ Overview by Application 71
7.2 Neuropathic Pain 74
7.3 Cancer Pain 75
7.4 Facial Pain and Migraine 76
7.5 Musculoskeletal Pain 77
7.6 Post-operative Pain 78
7.7 Chronic Back Pain 79
7.8 Arthritic Pain 80
7.9 Other Applications 81
8 Segmentation of Global ﾂ鮓ｹﾔｭｴｴ by Distribution Channel 82
8.1 ﾂ鮓ｹﾔｭｴｴ Overview by Distribution Channel 82
8.2 Hospitals Pharmacy 85
8.3 Online Pharmacy 86
8.4 Retail Pharmacy 87
9 Segmentation of Global ﾂ鮓ｹﾔｭｴｴ by Region 88
9.1 Geographic ﾂ鮓ｹﾔｭｴｴ Overview 2023-2033 88
9.2 North America ﾂ鮓ｹﾔｭｴｴ 2023-2033 by Country 93
9.2.1 Overview of North America ﾂ鮓ｹﾔｭｴｴ 93
9.2.2 U.S. 97
9.2.3 Canada 100
9.2.4 Mexico 102
9.3 European ﾂ鮓ｹﾔｭｴｴ 2023-2033 by Country 104
9.3.1 Overview of European ﾂ鮓ｹﾔｭｴｴ 104
9.3.2 Germany 108
9.3.3 U.K. 110
9.3.4 France 112
9.3.5 Spain 114
9.3.6 Italy 116
9.3.7 Russia 118
9.3.8 Rest of European ﾂ鮓ｹﾔｭｴｴ 120
9.4 Asia-Pacific ﾂ鮓ｹﾔｭｴｴ 2023-2033 by Country 122
9.4.1 Overview of Asia-Pacific ﾂ鮓ｹﾔｭｴｴ 122
9.4.2 Japan 126
9.4.3 China 129
9.4.4 Australia 131
9.4.5 India 133
9.4.6 South Korea 135
9.4.7 Rest of APAC Region 137
9.5 South America ﾂ鮓ｹﾔｭｴｴ 2023-2033 by Country 139
9.5.1 Argentina 143
9.5.2 Brazil 145
9.5.3 Chile 147
9.5.4 Rest of South America ﾂ鮓ｹﾔｭｴｴ 149
9.6 MEA ﾂ鮓ｹﾔｭｴｴ 2023-2033 by Country 150
9.6.1 UAE 154
9.6.2 Saudi Arabia 156
9.6.3 South Africa 158
9.6.4 Other National ﾂ鮓ｹﾔｭｴｴs 160
10 Competitive Landscape 161
10.1 Overview of Key Vendors 161
10.2 New Product Launch, Partnership, Investment, and M&A 164
10.3 Company Profiles 165
Abbott Laboratories Inc. 165
Baxter International Inc. 167
Boehringer Ingelheim International GmbH 168
Eli Lilly & Company 169
GlaxoSmithKline PLC 170
Johnson & Johnson 171
Merck & Co. Inc. 172
Novartis AG 173
Pfizer Inc. 174
Purdue Pharma L.P 175
Teva Pharmaceutical Industries Ltd. 176
11 Investing in Pain Management Drugs Industry: Risk Assessment and Management 177
11.1 Risk Evaluation of Global ﾂ鮓ｹﾔｭｴｴ 177
11.2 Critical Success Factors (CSFs) 184
RELATED REPORTS 187

List of Tables:

Table 1. Snapshot of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Balanced Perspective, 2023-2033 20
Table 2. World Economic Outlook, 2024-2036 24
Table 3. World Economic Outlook, 2022-2024 26
Table 4. Scenarios for Economic Impact of Ukraine Crisis 30
Table 5. Scenarios for Economic Impact of Israel-Palestine War 31
Table 6. World Health Spending by Region, $ bn, 2013-2020 36
Table 7. Main Product Trends and ﾂ鮓ｹﾔｭｴｴ Opportunities in Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ 40
Table 8. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 48
Table 9. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Pain Type, 2023-2033, $ mn 57
Table 10. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 62
Table 11. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Route of Administration, 2023-2033, $ mn 67
Table 12. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 72
Table 13. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Distribution Channel, 2023-2033, $ mn 83
Table 14. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Region, 2023-2033, $ mn 90
Table 15. Leading National Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023 and 2033, $ mn 92
Table 16. North America Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023-2033, $ mn 95
Table 17. U.S. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 99
Table 18. U.S. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 99
Table 19. U.S. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 99
Table 20. Canada Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 101
Table 21. Canada Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 101
Table 22. Canada Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 101
Table 23. Mexico Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 103
Table 24. Mexico Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 103
Table 25. Mexico Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 103
Table 26. Europe Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023-2033, $ mn 106
Table 27. Germany Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 109
Table 28. Germany Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 109
Table 29. Germany Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 109
Table 30. U.K. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 111
Table 31. U.K. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 111
Table 32. U.K. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 111
Table 33. France Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 113
Table 34. France Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 113
Table 35. France Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 113
Table 36. Spain Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 115
Table 37. Spain Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 115
Table 38. Spain Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 115
Table 39. Italy Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 117
Table 40. Italy Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 117
Table 41. Italy Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 117
Table 42. Russia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 119
Table 43. Russia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 119
Table 44. Russia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 119
Table 45. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Rest of Europe by Country, 2023-2033, $ mn 121
Table 46. APAC Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023-2033, $ mn 124
Table 47. Japan Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 128
Table 48. Japan Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 128
Table 49. Japan Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 128
Table 50. China Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 130
Table 51. China Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 130
Table 52. China Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 130
Table 53. Australia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 132
Table 54. Australia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 132
Table 55. Australia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 132
Table 56. India Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 134
Table 57. India Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 134
Table 58. India Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 134
Table 59. South Korea Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 136
Table 60. South Korea Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 136
Table 61. South Korea Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 136
Table 62. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Rest of APAC by Country/Region, 2023-2033, $ mn 138
Table 63. South America Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023-2033, $ mn 141
Table 64. Argentina Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 144
Table 65. Argentina Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 144
Table 66. Argentina Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 144
Table 67. Brazil Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 146
Table 68. Brazil Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 146
Table 69. Brazil Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 146
Table 70. Chile Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 148
Table 71. Chile Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 148
Table 72. Chile Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 148
Table 73. MEA Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023-2033, $ mn 152
Table 74. UAE Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 155
Table 75. UAE Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 155
Table 76. UAE Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 155
Table 77. Saudi Arabia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 157
Table 78. Saudi Arabia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 157
Table 79. Saudi Arabia Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 157
Table 80. South Africa Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, $ mn 159
Table 81. South Africa Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, $ mn 159
Table 82. South Africa Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, $ mn 159
Table 83. Abbott Laboratories Inc.: Company Snapshot 165
Table 84. Abbott Laboratories Inc.: Business Segmentation 166
Table 85. Abbott Laboratories Inc.: Product Portfolio 166
Table 86. List of Risk Factors and Weight Percentages/Theoretical Maximum 178
Table 87. Definition of GMD Relative Risk Index Number (Relative RIN) and GMD Risk Intensity Level (RIL) 180
Table 88. Risk Evaluation for Investing in Global ﾂ鮓ｹﾔｭｴｴ, 2023-2033 181
Table 89. Critical Success Factors and Key Takeaways 185

List of Figures:

Figure 1. Research Method Flow Chart 14
Figure 2. Bottom-up Approach and Top-down Approach for ﾂ鮓ｹﾔｭｴｴ Estimation 17
Figure 3. Global ﾂ鮓ｹﾔｭｴｴ Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033 19
Figure 4. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023-2033, $ mn 22
Figure 5. Impact of COVID-19 on Business 27
Figure 6. Primary Drivers and Impact Factors of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ 32
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 35
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 35
Figure 9. Primary Restraints and Impact Factors of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ 37
Figure 10. Porter窶冱 Fiver Forces Analysis of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ 43
Figure 11. Growth Opportunity Analysis by Product 47
Figure 12. Breakdown of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product, 2023-2033, % of Revenue 48
Figure 13. Global Addressable ﾂ鮓ｹﾔｭｴｴ Cap in 2024-2033 by Product, Value ($ mn) and Share (%) 49
Figure 14. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product: Opioids, 2023-2033, $ mn 50
Figure 15. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product: NSAIDS, 2023-2033, $ mn 51
Figure 16. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product: Anesthetics, 2023-2033, $ mn 52
Figure 17. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product: Anticonvulsants, 2023-2033, $ mn 53
Figure 18. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product: Anti-depressants, 2023-2033, $ mn 54
Figure 19. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Product: Non-narcotic Analgesics, 2023-2033, $ mn 55
Figure 20. Growth Opportunity Analysis by Pain Type 56
Figure 21. Breakdown of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Pain Type, 2023-2033, % of Sales Revenue 57
Figure 22. Global Addressable ﾂ鮓ｹﾔｭｴｴ Cap in 2024-2033 by Pain Type, Value ($ mn) and Share (%) 58
Figure 23. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Pain Type: Chronic Pain, 2023-2033, $ mn 59
Figure 24. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Pain Type: Acute Pain, 2023-2033, $ mn 60
Figure 25. Growth Opportunity Analysis by Drug Type 61
Figure 26. Breakdown of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type, 2023-2033, % of Sales Revenue 62
Figure 27. Global Addressable ﾂ鮓ｹﾔｭｴｴ Cap in 2024-2033 by Drug Type, Value ($ mn) and Share (%) 63
Figure 28. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type: Generic Drugs, 2023-2033, $ mn 64
Figure 29. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Drug Type: Branded Drugs, 2023-2033, $ mn 65
Figure 30. Growth Opportunity Analysis by Route of Administration 66
Figure 31. Breakdown of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Route of Administration, 2023-2033, % of Revenue 67
Figure 32. Global Addressable ﾂ鮓ｹﾔｭｴｴ Cap in 2024-2033 by Route of Administration, Value ($ mn) and Share (%) 68
Figure 33. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Route of Administration: Oral, 2023-2033, $ mn 69
Figure 34. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Route of Administration: Parental, 2023-2033, $ mn 70
Figure 35. Growth Opportunity Analysis by Application 71
Figure 36. Breakdown of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application, 2023-2033, % of Revenue 72
Figure 37. Global Addressable ﾂ鮓ｹﾔｭｴｴ Cap in 2024-2033 by Application, Value ($ mn) and Share (%) 73
Figure 38. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application: Neuropathic Pain, 2023-2033, $ mn 74
Figure 39. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application: Cancer Pain, 2023-2033, $ mn 75
Figure 40. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application: Facial Pain and Migraine, 2023-2033, $ mn 76
Figure 41. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application: Musculoskeletal Pain, 2023-2033, $ mn 77
Figure 42. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application: Post-operative Pain, 2023-2033, $ mn 78
Figure 43. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application: Chronic Back Pain, 2023-2033, $ mn 79
Figure 44. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application: Arthritic Pain, 2023-2033, $ mn 80
Figure 45. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Application: Other Applications, 2023-2033, $ mn 81
Figure 46. Growth Opportunity Analysis by Distribution Channel 82
Figure 47. Breakdown of Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Distribution Channel, 2023-2033, % of Revenue 83
Figure 48. Global Addressable ﾂ鮓ｹﾔｭｴｴ Cap in 2024-2033 by Distribution Channel, Value ($ mn) and Share (%) 84
Figure 49. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Distribution Channel: Hospitals Pharmacy, 2023-2033, $ mn 85
Figure 50. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Distribution Channel: Online Pharmacy, 2023-2033, $ mn 86
Figure 51. Global Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Distribution Channel: Retail Pharmacy, 2023-2033, $ mn 87
Figure 52. Global ﾂ鮓ｹﾔｭｴｴ Snapshot by Region 88
Figure 53. Growth Opportunity Analysis of Global ﾂ鮓ｹﾔｭｴｴ by Region 89
Figure 54. Geographic Spread of Worldwide Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023-2033, % of Sales Revenue 90
Figure 55. Global Addressable ﾂ鮓ｹﾔｭｴｴ Cap in 2024-2033 by Region, Value ($ mn) and Share (%) 91
Figure 56. North American Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023-2033, $ mn 94
Figure 57. Growth Opportunity Analysis of North America ﾂ鮓ｹﾔｭｴｴ by Country 94
Figure 58. Breakdown of North America Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023 and 2033, % of Revenue 95
Figure 59. Contribution to North America 2024-2033 Cumulative ﾂ鮓ｹﾔｭｴｴ by Country, Value ($ mn) and Share (%) 96
Figure 60. U.S. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023-2033, $ mn 98
Figure 61. Canada Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023-2033, $ mn 100
Figure 62. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Mexico, 2023-2033, $ mn 102
Figure 63. European Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023-2033, $ mn 105
Figure 64. Growth Opportunity Analysis of Europe ﾂ鮓ｹﾔｭｴｴ by Country 105
Figure 65. Breakdown of European Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023 and 2033, % of Revenue 106
Figure 66. Contribution to Europe 2024-2033 Cumulative ﾂ鮓ｹﾔｭｴｴ by Country, Value ($ mn) and Share (%) 107
Figure 67. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Germany, 2023-2033, $ mn 108
Figure 68. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in U.K., 2023-2033, $ mn 110
Figure 69. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in France, 2023-2033, $ mn 112
Figure 70. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Spain, 2023-2033, $ mn 114
Figure 71. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Italy, 2023-2033, $ mn 116
Figure 72. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Russia, 2023-2033, $ mn 118
Figure 73. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Rest of Europe, 2023-2033, $ mn 120
Figure 74. Asia-Pacific Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023-2033, $ mn 123
Figure 75. Growth Opportunity Analysis of Asia-Pacific ﾂ鮓ｹﾔｭｴｴ by Country 123
Figure 76. Breakdown of APAC Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023 and 2033, % of Revenue 124
Figure 77. Contribution to APAC 2024-2033 Cumulative ﾂ鮓ｹﾔｭｴｴ by Country, Value ($ mn) and Share (%) 125
Figure 78. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Japan, 2023-2033, $ mn 127
Figure 79. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in China, 2023-2033, $ mn 129
Figure 80. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Australia, 2023-2033, $ mn 131
Figure 81. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in India, 2023-2033, $ mn 133
Figure 82. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in South Korea, 2023-2033, $ mn 135
Figure 83. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Rest of APAC, 2023-2033, $ mn 137
Figure 84. South America Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ, 2023-2033, $ mn 140
Figure 85. Growth Opportunity Analysis of South America ﾂ鮓ｹﾔｭｴｴ by Country 140
Figure 86. Breakdown of South America Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023 and 2033, % of Revenue 141
Figure 87. Contribution to South America 2024-2033 Cumulative ﾂ鮓ｹﾔｭｴｴ by Country, Value ($ mn) and Share (%) 142
Figure 88. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Argentina, 2023-2033, $ mn 143
Figure 89. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Brazil, 2023-2033, $ mn 145
Figure 90. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Chile, 2023-2033, $ mn 147
Figure 91. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Rest of South America, 2023-2033, $ mn 149
Figure 92. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Middle East and Africa (MEA), 2023-2033, $ mn 151
Figure 93. Growth Opportunity Analysis of MEA ﾂ鮓ｹﾔｭｴｴ by Country 151
Figure 94. Breakdown of MEA Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ by Country, 2023 and 2033, % of Revenue 152
Figure 95. Contribution to MEA 2024-2033 Cumulative ﾂ鮓ｹﾔｭｴｴ by Country, Value ($ mn) and Share (%) 153
Figure 96. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in UAE, 2023-2033, $ mn 154
Figure 97. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in Saudi Arabia, 2023-2033, $ mn 156
Figure 98. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in South Africa, 2023-2033, $ mn 158
Figure 99. Pain Management Drugs ﾂ鮓ｹﾔｭｴｴ in the Rest of MEA, 2023-2033, $ mn 160
Figure 100. Growth Stage of Global Pain Management Drugs Industry over the Forecast Period 161
Figure 101. Comparison of Risk Factors by GMD RIN in 2023 181
Figure 102. GMD Relative RIN of Internal Risk Factors in 2023 on Radar Chart 182
Figure 103. GMD Relative RIN of External Risk Factors in 2023 on Radar Chart 182

Companies Mentioned:

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.